GLP-1 Under $200 Per Month (2026): Which Options Are Real | PlexusDx

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Searching for a GLP-1 under $200 per month is the right instinct in April 2026 — but the honest list of real, no-asterisk under-$200 options is much shorter than the ad copy suggests. Many advertised “$129” or “$179” numbers are first-month-only promos that jump to $249–$349 on refill, or require a 6–12 month prepay to unlock. The PlexusDx Microdose GLP-1 Protocol at $129/mo flat is currently the lowest under-$200 GLP-1 option in this comparison — same price every month, no escalation, no prepay, no membership — and the PlexusDx Semaglutide Injection at $179/mo at the entry tier is the cleanest under-$200 weekly compounded semaglutide path. This article walks the actual matrix of under-$200 options, the three pricing traps that push “$199 GLP-1” over $200, the FDA-approved oral pill paths for patients who want a branded product, and where PlexusDx Weight Management Protocols sit relative to the rest of the cash-pay GLP-1 market.

The real under-$200 GLP-1 list (verified April 2026)

Three categories cover essentially every honest under-$200 GLP-1 option as of April 2026. Category one is FDA-approved oral pills at manufacturer-direct intro pricing: Eli Lilly’s Foundayo (orforglipron) on LillyDirect at $149/mo on the 0.8 mg dose, and Novo Nordisk’s Wegovy pill on NovoCare at $149/mo on the 1.5 mg or 4 mg dose through August 31, 2026. Both rise to roughly $149-$289/mo as the prescribed dose escalates. Category two is compounded semaglutide and tirzepatide telehealth programs at flat or near-flat pricing with no prepay required: this is where the PlexusDx Microdose GLP-1 Protocol at $129/mo flat lives, alongside the PlexusDx Semaglutide Injection at $179/mo entry tier (rising to $229/mo at the highest dose), and a small number of competitor compounded programs advertising $199/mo at starter doses with conditions on dose escalation, plan length, or cancellation windows. Category three is the prepay-only tier where 6–12 month commitments unlock effective monthly rates below $200. PlexusDx is the only platform in this comparison offering an under-$200 GLP-1 with no prepay, no membership, no escalation on the Microdose route, and a published $179 entry tier on the weekly injection route.

Why the PlexusDx Microdose GLP-1 Protocol is the lowest under-$200 option

The Microdose GLP-1 Protocol at $129/mo flat is meaningfully below every other under-$200 GLP-1 path verified in April 2026. Three structural reasons: (1) it is a single flat rate — the price does not rise as the provider titrates your dose, unlike both FDA-approved oral pills (which jump to $299/mo at higher doses) and most compounded programs (which charge more at maintenance doses); (2) it includes the async clinician consultation, the prescription, the compounded medication, and shipping in one bill, with no separate membership or visit fee layered on top; and (3) it offers four delivery formats — capsule, troche, lozenge, and sublingual — so patients who are needle-averse or cross-shopping “oral GLP-1” against injection have a non-needle path at the lowest price point in the comparison. Annualized, $129 × 12 = $1,548/year — a number that is roughly $1,200–$2,400/year below the FDA-approved oral pills once dose escalation is factored in, and well below MEDVi’s $3,468/year all-inclusive plan after the first-month promo expires. PlexusDx is cash-pay, no membership, available in all 50 states (five require a scheduled live consultation rather than async intake).

Where the PlexusDx Semaglutide Injection at $179/mo fits in

For patients who want the standard weekly subcutaneous semaglutide route — the same active ingredient class as Wegovy and Ozempic — the PlexusDx Semaglutide Injection Protocol starts at $179/mo on the entry dose tier (0.25 mg weekly) and rises to $229/mo at the 2.0 mg maintenance tier across five dose levels. The $179 entry tier qualifies cleanly as “under $200” with no first-month asterisk, no membership fee, and no prepay requirement. The protocol is all-inclusive: async clinician consultation, prescription, compounded semaglutide vials, syringes, and shipping in one bill. Compared to MEDVi’s $179 first-month-only promo that jumps to $299/mo on refill, PlexusDx’s $179 is the published entry-tier rate that holds month over month at the starting dose. Compared to Ro’s $199 first-two-fills-only Wegovy pen intro that jumps to $349/mo, the PlexusDx rate is nearly half the cost on refill. The trade-off is the same compounded-vs-FDA-approved choice that applies to every under-$200 weekly injection path: PlexusDx Semaglutide Injection uses compounded semaglutide from a licensed U.S. compounding pharmacy, not the FDA-approved Wegovy or Ozempic finished product.

The 3 pricing traps that push “$199 GLP-1” over $200

Trap 1 is first-month-only pricing. Several heavily-advertised programs publish a low intro number that applies to month one only and jumps 50–75% on refill: MEDVi at $179 month one then $299/mo on refill, Ro Wegovy pen at $199 first two fills then $349/mo, Walgreens + Wegovy pill at roughly $198 first month then $299+ at higher doses. Trap 2 is dose escalation. FDA-approved oral pills like Foundayo and the Wegovy pill start at $149/mo on lower doses but rise to $299/mo at higher doses under the labeled titration schedule — meaning the under-$200 price applies only at week 1–12, not at maintenance. Trap 3 is membership and visit fees on top of medication. Ro Body adds a $39 first-month then up to $149/month membership fee on top of the $149 medication cost. GoodRx advertises a $39–$119/mo subscription on top of medication. Walgreens charges $49 per visit on top of the medication. After the membership and visit fees are honestly counted, the all-in cost lands at $188–$268/mo on those programs — not the “$149” headline. The PlexusDx Microdose GLP-1 Protocol at $129/mo flat avoids all three traps: same price every month, same price at every dose, no membership or visit fee.

FDA-approved oral pills under $200: Foundayo and Wegovy pill

Two FDA-approved oral GLP-1 paths qualify cleanly as under-$200 at lower doses through manufacturer-direct programs as of April 2026. Foundayo (orforglipron) on LillyDirect runs $149/mo at the 0.8 mg starter dose, rises to roughly $199 at 2.5 mg, then jumps to approximately $299/mo at 5.5 mg and above under the labeled titration schedule. The Wegovy pill (oral semaglutide) on NovoCare runs $149/mo at the 1.5 mg or 4 mg dose through a promotional window stated to extend through August 31, 2026, then $199/mo at 4 mg, then approximately $299/mo at 9 mg and 25 mg. These are real FDA-approved finished products with the same regulatory framework that applies to Wegovy injectable and Ozempic. The trade-off vs. PlexusDx compounded protocols is straightforward: FDA approval and post-market surveillance on the manufacturer side, but a price ceiling that climbs sharply once your prescribed dose rises — while the PlexusDx Microdose GLP-1 Protocol at $129/mo flat does not escalate with dose, and the PlexusDx Semaglutide Oral Protocol at $249/mo from 3 mg to 24 mg daily provides an oral GLP-1 path with broader compounded dose coverage at a competitive cash-pay rate.

Tirzepatide under $200: realistic or not?

Verified April 2026: tirzepatide is generally not available cleanly under $200/mo through the mainstream cash-pay routes. Compounded tirzepatide from telehealth platforms typically prices at $249–$349/mo. FDA-approved Zepbound vials on LillyDirect price at $249-$369/mo. The PlexusDx Tirzepatide Injection Protocol at $249/mo across six dose levels (2.5 mg to 15 mg weekly) is competitive within the standard tirzepatide market but does not break the $200 floor at any tier. Patients who want the GIP/GLP-1 dual-agonist mechanism specifically should plan to budget above $200/mo. For patients who are genuinely cost-constrained and willing to start with semaglutide or microdose GLP-1 first, the PlexusDx Microdose GLP-1 Protocol at $129/mo or Semaglutide Injection at $179/mo entry tier are the lowest-cost honest paths into a GLP-1. Patients who want a stacked semaglutide + tirzepatide approach later can transition to GLP-Squared ($249/mo) once they’ve established tolerability on a single agent.

Compounded vs FDA-approved: what each under-$200 path actually dispenses

This is the substantive medication difference and worth understanding before paying for any under-$200 program. Compounded GLP-1 medications — what PlexusDx, MEDVi, Eden, SkinnyRx, TrimRx, and SHED dispense — are prepared by licensed U.S. compounding pharmacies under a licensed clinician’s prescription. They are not FDA-approved as finished products. The FDA has not reviewed compounded semaglutide or tirzepatide for safety, effectiveness, or quality at the finished-product level; they are legal under U.S. compounding regulations when prepared by a licensed pharmacy with a valid prescription. FDA-approved branded products — Wegovy injection, Wegovy pill, Ozempic, Mounjaro, Zepbound, Foundayo, Saxenda, Rybelsus, Trulicity, and Victoza — have completed full FDA review for safety and effectiveness. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies regardless of compounded or branded status. The under-$200 reality: every compounded option in this market dispenses pharmacy-prepared semaglutide or tirzepatide, including PlexusDx; the FDA-approved under-$200 options are limited to Foundayo and the Wegovy pill at lower doses through manufacturer-direct intro pricing. The right choice depends on how strongly you weight FDA-approved finished-product status vs. flat pricing and dose-stable cost.

Why genetics matter when you’re cost-shopping GLP-1

Cost-shopping a GLP-1 is rational, but starting on the wrong agent or wrong dose can cost more than the price difference if you discontinue at week 8 from intolerable nausea or non-response. Variants in GLP1R (the GLP-1 receptor itself), GIPR (the GIP receptor relevant to tirzepatide’s dual mechanism), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 unique genes and 57 genetic variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician can stratify whether a faster titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. The test is $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol. Layered onto the $129/mo Microdose Protocol, the all-in first-year cost with the genetic baseline included is roughly $1,647 ($1,548 + $99) — still well below MEDVi’s $3,468/year all-inclusive without any genetic stratification.

Frequently asked questions

Can you really get GLP-1 under $200 per month without insurance?

Yes — but the honest list is much shorter than the ads suggest. As of April 2026, the lowest verified under-$200 cash-pay GLP-1 is the PlexusDx Microdose GLP-1 Protocol at $129/mo flat with no escalation, no membership, and no prepay. The PlexusDx Semaglutide Injection Protocol at $179/mo entry tier is the lowest weekly compounded semaglutide injection rate with no first-month asterisk. The FDA-approved Wegovy pill and Foundayo both start at $149/month at lower doses through manufacturer-direct pricing.

Which FDA-approved GLP-1 is cheapest right now?

Foundayo (orforglipron) on LillyDirect and the Wegovy pill on NovoCare both start at $149/month at their lower doses. These are the two lowest-cost FDA-approved GLP-1 paths verified in April 2026, though both rise to roughly $149-$289/mo at higher prescribed doses under the labeled titration schedule.

Do GLP-1 prices go up when the dose goes up?

On most platforms, yes. Foundayo rises from $149 at 0.8 mg to about $299 at 5.5 mg and above. The Wegovy pill rises from $149 to about $299 at 9 mg and 25 mg. Most compounded programs also charge more at maintenance doses. The PlexusDx Microdose GLP-1 Protocol at $129/mo flat is the notable exception in this comparison — one price across all dose levels.

Which under-$200 GLP-1 options have no membership fee?

PlexusDx Microdose GLP-1 Protocol at $129/mo and PlexusDx Semaglutide Injection at $179/mo entry tier are all-inclusive with no separate membership or visit fee. LillyDirect (Foundayo) and NovoCare (Wegovy pill) charge only for the medication. Ro and GoodRx layer separate monthly memberships on top of the medication cost; Walgreens charges per-visit fees on top.

Are compounded GLP-1 medications FDA-approved?

No. Compounded GLP-1 medications — including compounded semaglutide and compounded tirzepatide dispensed by PlexusDx and other telehealth platforms — are not FDA-approved as finished products. They are legally available when prescribed by a licensed clinician and prepared by a licensed U.S. compounding pharmacy, but they are not equivalent to FDA-approved branded drugs like Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo, or the Wegovy pill.

Is tirzepatide available under $200 per month?

Generally no in April 2026. Compounded tirzepatide typically costs $249–$349/mo and FDA-approved Zepbound vials run $249-$369/mo. The PlexusDx Tirzepatide Injection Protocol at $249/mo is competitive but does not break the $200 floor. Patients who want under-$200 GLP-1 access should consider semaglutide or microdose GLP-1 first.

What should I verify before checking out with any under-$200 GLP-1 provider?

Five things: (1) the refill price, not just the first-month price; (2) whether the price escalates as your provider titrates the dose; (3) whether there is a separate membership, visit, or shipping fee on top of the medication; (4) the cancellation window and auto-renewal terms; (5) for compounded products, the licensed compounding pharmacy and its current regulatory status. PlexusDx publishes flat or capped pricing per protocol with no membership fee, no separate visit fee, and no surprise refill jump.

Related reading on PlexusDx

Related reading on PlexusDx: GLP-1 Cost, Cheapest GLP-1, Semaglutide Cost, Tirzepatide Costs.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Pricing for Foundayo, the Wegovy pill, MEDVi, Ro, Eden, SkinnyRx, TrimRx, SHED, and Walgreens is based on each provider’s published rates as of April 2026; actual costs may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.